5-HT and HTR2B agonists promote cell proliferation and inhibit cell apoptosis in vitro, with silenced HTR2B blocking tumor growth in vivo, making it a potential drug target for pancreatic cancer treatment [77]. Here, HTR2B is linked to familial pancreatic carcinoma.